You are here: Industry Insights > Yervoy

News List

MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma pharmatimes
August 06, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb's (BMS) Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for the first-line treatment of adult patients with unresectable malignant pleural ...
EC green light for Opdivo plus Yervoy in metastatic colorectal cancer pharmatimes
July 01, 2021
The European Commission (EC) has approved Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy immunotherapy regimen for the treatment of certain metastatic colorectal patients (mCRC), the company announced 29th.
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients pharmatimes
June 16, 2021
Bristol Myers Squibb’s (BMS) immunotherapy combination Opdivo plus Yervoy has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of certain advanced bowel cancer patients.
Opdivo combos show OS benefit in advanced oesophageal cancer pharmatimes
June 10, 2021
Bristol Myers Squibb’s (BMS) immunotherapy Opdivo, when administered alongside chemotherapy or Yervoy, demonstrated significant overall survival (OS) benefit compared to chemotherapy alone in advanced/metastatic oesophageal cancer patients.
EC Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma americanpharmaceuticalreview
June 04, 2021
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).
Opdivo plus Yervoy moves closer to EU approval for dMMR/MSI-H colorectal cancer pharmatimes
May 26, 2021
Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy combination therapy has moved closer to EU approval for certain colorectal cancer patients, after scoring a positive opinion from the European Medicines Agency’s (EMA) Committee for ...
BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients pharmatimes
May 25, 2021
Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.
NICE 'no' for Opdivo/Yervoy lung cancer combo pharmatimes
April 13, 2021
The National Institute for Health and Care Excellence (NICE) has issued a preliminary no for NHS use of Bristol-Myers Squibb's Opdivo (nivolumab)/Yervoy (ipilimumab) combination for treating a certain lung cancer.
Bristol Myers Squibb get EC approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with chemotherapy for metastatic NSCLC expresspharma
November 09, 2020
Opdivo plus Yervoy-based combinations now indicated in the EU for three different advanced cancer types: non-small cell lung cancer, melanoma and renal cell carcinoma.
BMS’ Opdivo combo gets FDA approval for malignant pleural mesothelioma pharmaceutical-technology
October 10, 2020
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy (ipilimumab) for treating adults with unresectable malignant pleural mesothelioma (MPM).

Previous page 1 2 3 Next page